Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
New England Journal of MedicinePublished 13 February 2007
Laura Mauri, Wen-Hua Hsieh, Joseph M. Massaro, Kalon K.L. Ho, Ralph B. D’Agostino, Donald E. Cutlip
Citations1,441
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The incidence of stent thrombosis did not differ significantly between patients with drug-eluting stents and those with bare-metal stents in randomized clinical trials, although the power to detect small differences in rates was limited.
Abstract
The incidence of stent thrombosis did not differ significantly between patients with drug-eluting stents and those with bare-metal stents in randomized clinical trials, although the power to detect small differences in rates was limited.
Keywords
Medicine
New England Journal of MedicineA Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease
4,540 Citations1994Patrick W. Serruys, Peter de Jaegere +15 more
The clinical and angiographic outcomes were better in patients who received a stent than in those who received standard coronary angioplasty, however, this benefit was achieved at the cost of a significantly higher risk of vascular complications at the access site and a longer hospital stay.
New England Journal of MedicineA Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease
4,243 Citations1994David L. Fischman, Martin B. Leon +22 more
In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
New England Journal of MedicineSirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery
4,207 Citations2003Jeffrey W. Moses, Martin B. Leon +10 more
In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.
New England Journal of MedicineA Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
4,031 Citations2002Marie‐Claude Morice, Patrick W. Serruys +10 more
As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.
JAMAIncidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents
3,124 Citations2005Ιoannis Iakovou
New England Journal of MedicineA Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
2,739 Citations2004Gregg W. Stone, Stephen G. Ellis +10 more
As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
The LancetEarly and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
1,752 Citations2007Joost Daemen, Peter Wenaweser +14 more
Late stent thrombosis was encountered steadily with no evidence of diminution up to 3 years of follow-up, and Acute coronary syndrome at presentation and diabetes were independent predictors of stentThromBosis.
New England Journal of MedicineSafety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
1,619 Citations2007Gregg W. Stone, Jeffrey W. Moses +13 more
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluted stents than with bare-metal stents, and both drug-elution stents were associated with a marked reduction in target-lesion revascularization.
BiometrikaChecking the Cox model with cumulative sums of martingale-based residuals
1,423 Citations1993D. Y. Lin, L. J. Wei +1 more
Journal of the American College of CardiologyLate Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
1,301 Citations2006Matthias Pfisterer, Hans‐Peter Brunner‐La Rocca +8 more
After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel revascularization is maintained but has to be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis.
CirculationRandomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions
1,017 Citations2003Antonio Colombo, J Drzewiecki +10 more
Compared with a bare metal stent, paclitaxel-eluting stents reduced in-stent neointimal formation and restenosis and improved 12-month clinical outcome of patients with single de novo coronary lesions.
The LancetSirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)
955 Citations2003Joachim Schofer, Michael Schlüter +5 more
Sirolimus-eluting stents are better than bare-metal stents for treatment of single long atherosclerotic lesions in a coronary vessel smaller than 3 mm in diameter.
JAMAClopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
870 Citations2006Eric L. Eisenstein, Kevin J. Anstrom +11 more
The extended use of clopidogrel in patients with DES may be associated with a reduced risk for death and death or MI, and the appropriate duration for clopIDogrel administration can only be determined within the context of a large-scale randomized clinical trial.
CirculationTAXUS I
868 Citations2003Eberhard Grube, Sigmund Silber +5 more
In this feasibility trial, the TAXUS slow-release stent was well tolerated and showed promise for treatment of coronary lesions, with significant reductions in angiographic and intravascular ultrasound measures of restenosis.
CirculationStent Thrombosis in the Modern Era
852 Citations2001Donald E. Cutlip, Donald S. Baim +8 more
CirculationOne-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent
763 Citations2004Gregg W. Stone, Stephen G. Ellis +10 more
The relative efficacy reported at 9 months for the polymer-based, paclitaxel-eluting TAXUS stent compared with the EXPRESS stent is preserved and continues to increase at 1 year, with no safety concerns apparent.
JAMAComparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease
762 Citations2005Gregg W. Stone, Stephen G. Ellis +11 more
Journal of the American College of CardiologyLate Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents
661 Citations2005Andrew T.L. Ong, Eugène McFadden +4 more
Angiographically proven late stent thrombosis occurs with an incidence of at least 0.35% (95% confidence limits 0.17% to 0.72%) in patients treated with DES, and may also occur when patients are stable on antiplatelet monotherapy.
Journal of the American College of CardiologyThe Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)
579 Citations2004Érick Schampaert, Eric A. Cohen +6 more
In patients with long lesions in small vessels, the SES dramatically reduces the risk of restenosis at eight months, translating into an excellent clinical outcome at nine months.
Journal of the American College of CardiologyDrug-eluting stent thrombosis
543 Citations2005Raúl Moreno, Cristina Fernández +8 more
Drug-eluting stents do not increase the risk of stent thrombosis after DES implantation, at least under appropriate anti-platelet therapy, and the relationship between the rate of ST and the stented length is related to stent length.
CirculationAnalysis of 1-Year Clinical Outcomes in the SIRIUS Trial
516 Citations2004David R. Holmes, Martin B. Leon +10 more
Placement of the sirolimus-eluting stent results in continued clinical improvement at 1 year after initial implantation, with significant reduction in clinical restenosis as defined by target-lesion revascularization.
European Heart JournalMortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
483 Citations2006A. J. Nordmann, Matthias Briel +1 more
ACC Current Journal ReviewComparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial
435 Citations2005Gregg W. Stone, Stephen G. Ellis +1 more
Compared with a bare metal stent, implantation of the paclitaxel-eluting stent in a patient population with complex lesions effectively reduces clinical and angiographic restenosis.
CirculationPercutaneous Coronary Intervention in the Current Era Compared With 1985–1986
317 Citations2000David O. Williams, Richard Holubkov +18 more
Although Dynamic Registry patients had more unstable and complex coronary disease than those in the 1985–1986 Registry, their rate of procedural success was higher whereas rates of complications and subsequent CABG were lower.
PubMedPaclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
273 Citations2006Gregg W. Stone, Stephen G. Ellis +9 more
Treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting stents rather than angioplasty followed by VBT reduces clinical and angiographic restenosis at 9 months and improves event-free survival.
JAMASirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents
247 Citations2006David R. Holmes, Paul Teirstein +10 more
Sirolimus-eluting stents result in superior clinical and angiographic outcomes compared with vascular brachytherapy for the treatment of restenosis within a bare-metal stent.
Journal of the American College of CardiologyLate total occlusion after intracoronary brachytherapy for patients with in-stent restenosis
219 Citations2000Ron Waksman, Balram Bhargava +7 more
Intracoronary radiation for patients with in-stent restenosis is associated with a high rate of LTO and restenting may contribute late thrombosis, and prolonged antiplatelet therapy should be considered for these patients.
Journal of the American College of CardiologySubacute stent thrombosis: Evolving issues and current concepts
211 Citations1996Koon‐Hou Mak, Guido Belli +2 more
Clinical studies suggest factors associated with a heightened risk of stent thrombosis, many of which can be avoided with proper case selection and contemporary techniques.
CirculationRandomized Trial of <sup>90</sup> Sr/ <sup>90</sup> Y β-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis
210 Citations2002Jeffrey J. Popma, Mohan Suntharalingam +13 more
This is the first multicenter, blinded, and randomized trial of intracoronary radiation with the use of a 90Sr/90Y β-source for the treatment of in-stent restenosis, and the primary end point, ie, clinically driven target-vessel revascularization by 8 months, was observed.